Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

Background: Despite growing interest in cutaneous adverse events (CAEs) and their management in patients with cancer, they are often underreported and there are no extensive data on their impact on quality of life (QoL). Healthcare professionals should consider this issue in order to minimize its ne...

Full description

Bibliographic Details
Main Authors: Hae-Jin Suh Oh, Ángeles Flórez Menéndez, Víctor Sacristán Santos, Francisca Fernández Ribeiro, Lucía Vilanova-Trillo, Manuel Constenla Figueiras, Manuel Pereiro Ferreiros
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-08-01
Series:Drugs in Context
Subjects:
Online Access:https://www.drugsincontext.com/cutaneous-adverse-events-and-quality-of-life-in-outpatients-receiving-anticancer-agents:-results-from-an-observational,-cross-sectional-study
_version_ 1818519469168787456
author Hae-Jin Suh Oh
Ángeles Flórez Menéndez
Víctor Sacristán Santos
Francisca Fernández Ribeiro
Lucía Vilanova-Trillo
Manuel Constenla Figueiras
Manuel Pereiro Ferreiros
author_facet Hae-Jin Suh Oh
Ángeles Flórez Menéndez
Víctor Sacristán Santos
Francisca Fernández Ribeiro
Lucía Vilanova-Trillo
Manuel Constenla Figueiras
Manuel Pereiro Ferreiros
author_sort Hae-Jin Suh Oh
collection DOAJ
description Background: Despite growing interest in cutaneous adverse events (CAEs) and their management in patients with cancer, they are often underreported and there are no extensive data on their impact on quality of life (QoL). Healthcare professionals should consider this issue in order to minimize its negative impact on QoL and improve patient outcomes. This study evaluates the impact of CAEs on QoL in outpatients receiving anticancer drugs and aims to determine the differences in QoL between conventional chemotherapy versus targeted therapies. Methods: A total of 114 cancer patients with CAEs were included in this observational, cross-sectional study. Patient-reported outcomes instruments (Functional Assessment of Cancer Therapy – General, Dermatology Life Quality Index, and Skindex-16) were used. Results: Mean scores in QoL indices were 65.3±13.4, 8.4±5, and 30.8±16.9 in Functional Assessment of Cancer Therapy – General, Dermatology Life Quality Index, and Skindex-16, respectively. The CAEs that had the greatest impact on dermatologic-related QoL were hand–foot skin reaction, rash, palmo-plantar erythrodysesthesia, and papulopustular eruption. No significant differences in QoL indices according to the type of treatment (conventional chemotherapy versus targeted therapy) were observed. Conclusions: CAEs, and particularly hand–foot toxicities, rashes, and papulopustular eruptions, can have an impact on QoL in outpatients receiving anticancer drugs as evaluated with three different patient-reported outcomes instruments. No differences in QoL related to CAEs were observed between conventional chemotherapy and targeted therapy.
first_indexed 2024-12-11T01:24:37Z
format Article
id doaj.art-49721c07f52942ee8c6fcc478299ebdb
institution Directory Open Access Journal
issn 1740-4398
1740-4398
language English
last_indexed 2024-12-11T01:24:37Z
publishDate 2020-08-01
publisher BioExcel Publishing Ltd
record_format Article
series Drugs in Context
spelling doaj.art-49721c07f52942ee8c6fcc478299ebdb2022-12-22T01:25:35ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982020-08-01911010.7573/dic.2020-6-6Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional studyHae-Jin Suh OhÁngeles Flórez MenéndezVíctor Sacristán SantosFrancisca Fernández RibeiroLucía Vilanova-TrilloManuel Constenla FigueirasManuel Pereiro FerreirosBackground: Despite growing interest in cutaneous adverse events (CAEs) and their management in patients with cancer, they are often underreported and there are no extensive data on their impact on quality of life (QoL). Healthcare professionals should consider this issue in order to minimize its negative impact on QoL and improve patient outcomes. This study evaluates the impact of CAEs on QoL in outpatients receiving anticancer drugs and aims to determine the differences in QoL between conventional chemotherapy versus targeted therapies. Methods: A total of 114 cancer patients with CAEs were included in this observational, cross-sectional study. Patient-reported outcomes instruments (Functional Assessment of Cancer Therapy – General, Dermatology Life Quality Index, and Skindex-16) were used. Results: Mean scores in QoL indices were 65.3±13.4, 8.4±5, and 30.8±16.9 in Functional Assessment of Cancer Therapy – General, Dermatology Life Quality Index, and Skindex-16, respectively. The CAEs that had the greatest impact on dermatologic-related QoL were hand–foot skin reaction, rash, palmo-plantar erythrodysesthesia, and papulopustular eruption. No significant differences in QoL indices according to the type of treatment (conventional chemotherapy versus targeted therapy) were observed. Conclusions: CAEs, and particularly hand–foot toxicities, rashes, and papulopustular eruptions, can have an impact on QoL in outpatients receiving anticancer drugs as evaluated with three different patient-reported outcomes instruments. No differences in QoL related to CAEs were observed between conventional chemotherapy and targeted therapy.https://www.drugsincontext.com/cutaneous-adverse-events-and-quality-of-life-in-outpatients-receiving-anticancer-agents:-results-from-an-observational,-cross-sectional-studycutaneous adverse eventspatient-reported outcomesquality of lifetargeted therapies
spellingShingle Hae-Jin Suh Oh
Ángeles Flórez Menéndez
Víctor Sacristán Santos
Francisca Fernández Ribeiro
Lucía Vilanova-Trillo
Manuel Constenla Figueiras
Manuel Pereiro Ferreiros
Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study
Drugs in Context
cutaneous adverse events
patient-reported outcomes
quality of life
targeted therapies
title Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study
title_full Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study
title_fullStr Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study
title_full_unstemmed Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study
title_short Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study
title_sort cutaneous adverse events and quality of life in outpatients receiving anticancer agents results from an observational cross sectional study
topic cutaneous adverse events
patient-reported outcomes
quality of life
targeted therapies
url https://www.drugsincontext.com/cutaneous-adverse-events-and-quality-of-life-in-outpatients-receiving-anticancer-agents:-results-from-an-observational,-cross-sectional-study
work_keys_str_mv AT haejinsuhoh cutaneousadverseeventsandqualityoflifeinoutpatientsreceivinganticanceragentsresultsfromanobservationalcrosssectionalstudy
AT angelesflorezmenendez cutaneousadverseeventsandqualityoflifeinoutpatientsreceivinganticanceragentsresultsfromanobservationalcrosssectionalstudy
AT victorsacristansantos cutaneousadverseeventsandqualityoflifeinoutpatientsreceivinganticanceragentsresultsfromanobservationalcrosssectionalstudy
AT franciscafernandezribeiro cutaneousadverseeventsandqualityoflifeinoutpatientsreceivinganticanceragentsresultsfromanobservationalcrosssectionalstudy
AT luciavilanovatrillo cutaneousadverseeventsandqualityoflifeinoutpatientsreceivinganticanceragentsresultsfromanobservationalcrosssectionalstudy
AT manuelconstenlafigueiras cutaneousadverseeventsandqualityoflifeinoutpatientsreceivinganticanceragentsresultsfromanobservationalcrosssectionalstudy
AT manuelpereiroferreiros cutaneousadverseeventsandqualityoflifeinoutpatientsreceivinganticanceragentsresultsfromanobservationalcrosssectionalstudy